HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.
about
Uncovering viral protein-protein interactions and their role in arenavirus life cycleHIV type 1 Gag as a target for antiviral therapyHIV Genome-Wide Protein Associations: a Review of 30 Years of ResearchDiversity and Inter-Connections in the CXCR4 Chemokine Receptor/Ligand Family: Molecular PerspectivesStructural and functional comparisons of retroviral envelope protein C-terminal domains: still much to learnUnderstanding the process of envelope glycoprotein incorporation into virions in simian and feline immunodeficiency virusesThe role of matrix in HIV-1 envelope glycoprotein incorporationRab27a controls HIV-1 assembly by regulating plasma membrane levels of phosphatidylinositol 4,5-bisphosphateA Single-Cell Platform for Monitoring Viral Proteolytic Cleavage in Different Cellular CompartmentsCrystal Structure of a Soluble Cleaved HIV-1 Envelope TrimerThe Roles of Syncytin-Like Proteins in Ruminant PlacentationFangchinoline inhibits human immunodeficiency virus type 1 replication by interfering with gp160 proteolytic processingAllosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivityA Novel Two-Tag System for Monitoring Transport and Cleavage through the Classical Secretory Pathway - Adaptation to HIV Envelope ProcessingFunctional organization of the HIV lipid envelopeC-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic.Optical trapping of individual human immunodeficiency viruses in culture fluid reveals heterogeneity with single-molecule resolution.Recombinant expression, purification, and biophysical characterization of the transmembrane and membrane proximal domains of HIV-1 gp41.HIV-1 Gag, Envelope, and Extracellular Determinants Cooperate To Regulate the Stability and Turnover of Virological Synapses.DNAVaxDB: the first web-based DNA vaccine database and its data analysis.Comparative analysis of the fusion efficiency elicited by the envelope glycoprotein V1-V5 regions derived from human immunodeficiency virus type 1 transmitted perinatally.HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells.HIV-1 interacts with human endogenous retrovirus K (HML-2) envelopes derived from human primary lymphocytes.Membrane fusion and cell entry of XMRV are pH-independent and modulated by the envelope glycoprotein's cytoplasmic tailThe tale of the long tail: the cytoplasmic domain of HIV-1 gp41.The stem of vesicular stomatitis virus G can be replaced with the HIV-1 Env membrane-proximal external region without loss of G function or membrane-proximal external region antigenic properties.Intercellular adhesion molecule 1 promotes HIV-1 attachment but not fusion to target cells.Insights into vaccine development for acquired immune deficiency syndrome from crystal structures of human immunodeficiency virus-1 gp41 and equine infectious anemia virus gp45.Retromer regulates HIV-1 envelope glycoprotein trafficking and incorporation into virions.Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.Increased functional stability and homogeneity of viral envelope spikes through directed evolution.Super-resolution microscopy reveals specific recruitment of HIV-1 envelope proteins to viral assembly sites dependent on the envelope C-terminal tail.Detailed topology mapping reveals substantial exposure of the "cytoplasmic" C-terminal tail (CTT) sequences in HIV-1 Env proteins at the cell surface.Optimized Infectivity of the Cell-Free Single-Cycle Human Immunodeficiency Viruses Type 1 (HIV-1) and Its Restriction by Host Cells.Human Ubc9 is involved in intracellular HIV-1 Env stability after trafficking out of the trans-Golgi network in a Gag dependent manner.Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.HIV-1 envelope glycoprotein variable loops are indispensable for envelope structural integrity and virus entry.Study of the HIV-2 Env cytoplasmic tail variability and its impact on Tat, Rev and Nef.Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.
P2860
Q24611407-AB56AAD6-5AAE-412B-A0B5-30424387A7C3Q24614498-692F2889-B5F3-4236-9123-E10AA420FA3FQ26746070-EE0DC7D7-D120-4731-9DAE-DA836F1D97CCQ26782778-D8BF635E-518E-452B-99A2-7EC16F06040FQ26862369-933C123E-2BEF-4CD5-853D-781FE3B7E958Q27021655-668A0137-82BC-450A-B87A-596895EFCABAQ27023106-C40AB7EB-EFA7-48AC-8030-C3FCC4D7DD9EQ27310788-1475D346-C57C-4560-BF91-2B5094F78C95Q27468663-58434B0E-2692-4360-98E3-972B5C65C14AQ27680496-1DA80D3A-B720-47F1-BF5A-E88019303439Q28086836-EA57BF04-E8D2-49D4-AF2A-FD194A564871Q28480389-148CDA40-20E1-4E5D-AB2D-4B9E6A7835CEQ28485983-C50AF9B7-4EAA-4187-BBF6-C8D4CB50ACBFQ28533980-D924304B-47CA-49C1-8222-9A156356699BQ28828700-08F7D1AE-E5E2-4A19-9BC4-A028EA45BAB6Q30422545-024F3BAA-7B4C-45DC-81BE-39843126FF26Q30586117-CFD1BD60-1635-402B-BD77-DDD79E78DE96Q30601090-3E17D688-DAC9-4DE0-AD58-634311039C03Q30781846-820F90C1-3713-4E42-B129-56104F43284FQ30841376-936CF8EA-EDEC-48D1-8178-39BB7625B107Q33879282-7BF0F7AE-2001-4E15-AEF0-5AF34E5015E8Q33887674-C4BA6AAD-A4D1-4294-B239-B0DC77FCB600Q33887743-EC6BBA1C-A751-4799-B5AE-A6382C102ED3Q34221609-640622DA-00E2-48A6-9D4D-5DC9141CCD4AQ34306883-A98495C9-82F4-43E4-A804-8C9633236844Q34399656-F10CA79A-4965-4BDD-8A1E-0407B4566501Q34412803-AB3A6D98-CCDB-446E-B0A5-5C625634E8D0Q34485027-CB39732B-20F1-422C-899D-805222CCF432Q34506932-6A5C36C9-BADE-4710-845B-C11D23DAC3E9Q34551010-D05253F2-7A78-4A97-B70F-20AB783BDC69Q34611144-195156A1-B7CB-4589-A71F-B5235B23FC21Q34611178-969D6DDD-68AF-4844-8FE8-27301C1274C0Q34750051-997CBD5D-6FBD-4E1C-94D7-ED493D8E71E7Q34794784-2086017A-0E07-4423-893B-8D5D8B64A9EEQ34828531-8C2EA293-E0A6-4410-99F1-1E6894A83D1DQ34847834-B2013B06-BBA6-4036-95C7-7355AED63ED8Q34869927-E7A02114-1860-419D-9B6F-07383737B338Q34924647-CFEE2EE5-7622-429C-8426-C5E82F9FE9D2Q35041167-A2CD69D0-C829-4138-A4F7-C1D7E3F4EE20Q35061529-27F03F32-DCB8-4D1E-9B0B-1C9F2D899243
P2860
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.
@ast
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.
@en
type
label
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.
@ast
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.
@en
prefLabel
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.
@ast
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.
@en
P2093
P2860
P1476
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.
@en
P2093
Benjamin G Luttge
Eric O Freed
Mary Ann Checkley
P2860
P304
P356
10.1016/J.JMB.2011.04.042
P407
P577
2011-07-01T00:00:00Z